NCT03695107Unknown不适用
Clinical Study on the Effect of PTH on CYP3A4 Activity
The Third Xiangya Hospital of Central South University1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2019年10月2日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- the concentration of nifedipine
研究概览
简要总结
Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4 expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chinese male or female subjects with an age of 18 or older were included;
- •The clinical physician diagnosed CKD with hypertension;
- •The physician decided that nifedipine controlled release tablets should be given.
- •Subjects agree to the study protocol, clinical and follow-up time, and sign the informed consent after the approval of the ethics committee;
- •Subjects will be able to communicate well with the investigator and will be able to complete the study as required.
排除标准
- •Patients with CKD requiring dialysis treatment;
- •Other clinical reasons that may be considered inappropriate for inclusion by clinicians.
研究组 & 干预措施
XBDP1-
干预措施: Nifedipine controlled released tablets (Drug)
XBDP2-
干预措施: Nifedipine controlled released tablets (Drug)
结局指标
主要结局
the concentration of nifedipine
时间窗: at 5-7days
the concentration of nifedipine
次要结局
- 24-hour ambulatory blood pressure(at 1 day and 7day)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
4 期
Parathyroid Hormone for the Treatment of Humerus FracturesShoulder FracturesNCT01687374Hvidovre University Hospital72
已完成
不适用
CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid TumoursSolid Tumor, AdultProstate CancerNCT05518799The Netherlands Cancer Institute18
已完成
1 期
A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211HealthyNCT01568411Glycyx Therapeutics20
已完成
1 期
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsHealthy VolunteersNCT05994807DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company33
已完成
1 期
Effect of Itraconazole on the Pharmacokinetics of BIIB074Neuropathic PainNCT02698267Biogen16